ArticlePediatric cardiology2026
Maternal Hyperoxygenation for Prenatal Risk Stratification of Pulmonary Venous Obstruction in Total Anomalous Pulmonary Venous Return.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary venous obstruction (PVO) is a major determinant of early morbidity and mortality in neonates with total anomalous pulmonary venous return (TAPVR). Accurate prenatal identification of obstructed TAPVR remains challenging due to low pulmonary blood flow in fetal circulation. Maternal hyperoxygenation (MHO) increases fetal pulmonary blood flow and may unmask clinically significant obstruction. We retrospectively reviewed three fetuses with prenatally diagnosed TAPVR who underwent late‑gestation fetal echocardiography with MHO testing. Doppler indices of pulmonary vasoreactivity and vertical vein (VV) flow were assessed at baseline and during MHO and correlated with postnatal clinical outcomes. All fetuses demonstrated preserved pulmonary vasoreactivity during MHO. One fetus had no Doppler evidence of PVO at rest or during MHO and had a stable postnatal course without emergent intervention. One fetus demonstrated elevated VV velocities at baseline that worsened during MHO and required emergent surgical repair shortly after birth. In the third fetus, VV Doppler findings were normal at baseline but became abnormal during MHO, accurately predicting postnatal clinical deterioration and the need for early catheter‑based intervention. These findings suggest that MHO testing can unmask occult pulmonary venous obstruction in fetal TAPVR and may improve prenatal risk stratification and perinatal planning.
Indexed as
Identifiers
42700246What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.